Human challenge models: tools to accelerate the development of malaria vaccines

被引:20
|
作者
Cooper, Martha M. [1 ]
Loiseau, Claire [1 ]
McCarthy, James S. [2 ]
Doolan, Denise L. [1 ]
机构
[1] James Cook Univ, Australian Inst Trop Hlth & Med, Ctr Mol Therapeut, Cairns, Australia
[2] QIMR Berghofer Med Res Inst, Infect Dis Programme, Brisbane, Qld, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Malaria; human challenge models; vaccines; drugs; diagnostics; tools; TROPHOZOITE-INDUCED INFECTIONS; PLASMODIUM-FALCIPARUM INFECTION; PARASITE MULTIPLICATION RATES; DIRECT VENOUS INOCULATION; TO-BLOOD INOCULA; RETROSPECTIVE EXAMINATION; SPOROZOITE CHALLENGE; IMMUNE-RESPONSES; PFSPZ VACCINE; GROWTH-RATES;
D O I
10.1080/14760584.2019.1580577
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Malaria challenge models, where healthy human volunteers are intentionally infected with Plasmodium species parasites under controlled conditions, can be undertaken in several well-defined ways. These challenge models enable evaluation of the kinetics of parasite growth and clearance, host-pathogen interactions and the host immune response. They can facilitate discovery of candidate diagnostic biomarkers and novel vaccine targets. As translational tools they can facilitate testing of candidate vaccines and drugs and evaluation of diagnostic tests. Areas covered: Until recently, malaria human challenge models have been limited to only a few Plasmodium falciparum strains and used exclusively in malaria-naive volunteers in non-endemic regions. Several recent advances include the use of alternate P. falciparum strains and other species of Plasmodia, as well as strains attenuated by chemical, radiation or genetic modification, and the conduct of studies in pre-exposed individuals. Herein, we discuss how this diversification is enabling more thorough vaccine efficacy testing and informing rational vaccine development. Expert opinion: The ability to comprehensively evaluate vaccine efficacy in controlled settings will continue to accelerate the translation of candidate malaria vaccines to the clinic, and inform the development and optimisation of potential vaccines that would be effective against multiple strains in geographically and demographically diverse settings.
引用
下载
收藏
页码:241 / 251
页数:11
相关论文
共 50 条
  • [1] Malaria vaccines:: using models of immunity and functional genomics tools to accelerate the development of vaccines against Plasmodium falciparum
    Duffy, PE
    Krzych, U
    Francis, S
    Fried, M
    VACCINE, 2005, 23 (17-18) : 2235 - 2242
  • [2] Experimental human challenge infections can accelerate clinical malaria vaccine development
    Robert W. Sauerwein
    Meta Roestenberg
    Vasee S. Moorthy
    Nature Reviews Immunology, 2011, 11 : 57 - 64
  • [3] Experimental human challenge infections can accelerate clinical malaria vaccine development
    Sauerwein, Robert W.
    Roestenberg, Meta
    Moorthy, Vasee S.
    NATURE REVIEWS IMMUNOLOGY, 2011, 11 (01) : 57 - 64
  • [4] Vaccines against leishmaniasis: using controlled human infection models to accelerate development
    Parkash, Vivak
    Kaye, Paul M.
    Layton, Alison M.
    Lacey, Charles J.
    EXPERT REVIEW OF VACCINES, 2021, 20 (11) : 1407 - 1418
  • [5] A challenge for the development of malaria vaccines: Polymorphic target antigens
    Sutherland, Colin
    PLOS MEDICINE, 2007, 4 (03) : 413 - 414
  • [6] Vaccines to Accelerate Malaria Elimination and Eventual Eradication
    Healer, Julie
    Cowman, Alan F.
    Kaslow, David C.
    Birkett, Ashley J.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (09):
  • [7] Promising cutting-edge technologies and tools to accelerate the discovery and development of new vaccines
    Ulmer, Jeffrey B.
    Sztein, Marcelo B.
    CURRENT OPINION IN IMMUNOLOGY, 2011, 23 (03) : 374 - 376
  • [8] TB biomarkers, TB correlates and human challenge models: New tools for improving assessment of new TB vaccines
    Kaufmann, Stefan H. E.
    Fortune, Sarah
    Pepponi, Ilaria
    Ruhwald, Morten
    Schrager, Lewis K.
    Ottenhoff, Tom H. M.
    TUBERCULOSIS, 2016, 99 : S8 - S11
  • [9] DEVELOPMENT OF MALARIA VACCINES
    PERRIN, LH
    SIMITSEK, P
    SRIVASTAVA, I
    TROPICAL AND GEOGRAPHICAL MEDICINE, 1988, 40 (03): : S6 - S21
  • [10] How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
    Giersing, Birgitte K.
    Porter, Chad K.
    Kotloff, Karen
    Neels, Pieter
    Cravioto, Alejandro
    MacLennan, Calman A.
    VACCINE, 2019, 37 (34) : 4778 - 4783